Paper information and key findings
Single-cell transcriptomics identifies a convergent activation state of conventional dendritic cells (cDCs) shared by type 1 and type 2 cDCs (cDC1s and cDC2s). These activated DCs (actDCs) are characterized by co-expression of T cell-stimulating and inhibitory molecules. Here, we examined the functional contribution of actDCs to anti-tumor immunity by developing mouse models that leverage CCR7 expression to conditionally label or ablate actDCs. The capacity of cDCs to stimulate tumor-specific cytotoxic T lymphocytes (CTLs) was restricted to the actDC state. cDC1- and cDC2-derived actDCs supported CTL priming through cross-presentation and cross-dressing, respectively, with the latter occurring in a cancer type-dependent manner. actDCs were required for the activation of naive CTLs in tumor-draining lymph nodes and for sustaining effector CTL function within tumors. Consequently, ablation of actDCs impaired spontaneous tumor control and responses to immune checkpoint blockade or adoptive T cell therapy. Thus, the actDC state emerges as a critical determinant of cDC-mediated anti-tumor immunity.
Single-cell transcriptomics identifies a convergent activation state of conventional dendritic cells (cDCs) shared by type 1 and type 2 cDCs (cDC1s and cDC2s). These activated DCs (actDCs) are characterized by co-expression of T cell-stimulating and inhibitory molecules. Here, we examined the functional contribution of actDCs to anti-tumor immunity by developing mouse models that leverage CCR7 expression to conditionally label or ablate actDCs. The capacity of cDCs to stimulate tumor-specific cytotoxic T lymphocytes (CTLs) was restricted to the actDC state. cDC1- and cDC2-derived actDCs supported CTL priming through cross-presentation and cross-dressing, respectively, with the latter occurring in a cancer type-dependent manner. actDCs were required for the activation of naive CTLs in tumor-draining lymph nodes and for sustaining effector CTL function within tumors. Consequently, ablation of actDCs impaired spontaneous tumor control and responses to immune checkpoint blockade or adoptive T cell therapy. Thus, the actDC state emerges as a critical determinant of cDC-mediated anti-tumor immunity.
Institute Authors
Group leader
Hear about the role of activated dendritic cells in cancer immunity, from paper first author, Maria Koufaki.
Annual Report 2025
2025 Annual Report
11 November 2026
11 November 2026
https://www.sciencedirect.com/science/article/pii/S2666634026003387?via%3Dihub
Bacteria inside kidney tumors associate with myeloid inflammation and disease progression: A TRACERx Renal study
23 October 2026
Institute Authors (1)
Samra Turajlić
Research Group
Cancer Dynamics
23 October 2026
https://royalsocietypublishing.org/rsob/article/16/8/260089/482862/CDK1-Cyclin-B-mediated-phosphorylation-of-PP2A-B56
CDK1-Cyclin B mediated phosphorylation of PP2A-B56 on B56Par1.T73T75 controls mitotic entry timing and Schizosaccharomyces pombe cell size
19 August 2026
Institute Authors (3)
Lenka Halova, Duncan Smith, Iain Hagan
Labs & Facilities
Biological Mass Spectrometry
Research Group
Cell Division
19 August 2026
https://www.cell.com/immunity/fulltext/S1074-7613(26)00278-5
CCR7+ activated dendritic cells are essential for spontaneous and immunotherapy-driven anti-tumor immunity
4 August 2026
Institute Authors (10)
Erin Richardson, Shih-Chieh Chiang, Massimo Russo, Charles Earnshaw, Anna Pidoux, Poppy Dunn, Sudhakar Sahoo, Antonia Banyard, Natalia Moncaut, Santiago Zelenay
Labs & Facilities
BRU Experimental Team, Computational Biology Support, Genome Editing and Mouse Models, Mass and Flow Cytometry, Transgenic Breeding Team
Research Group
Cancer Inflammation and Immunity
4 August 2026
https://www.cell.com/cell/fulltext/S0092-8674(26)00522-2
Plasma signals of lung tumor promotion for molecular cancer prevention
25 June 2026
Institute Authors (1)
William Hill
Research Group
Cancer Origins
25 June 2026
https://link.springer.com/article/10.1038/s44319-026-00809-1
PKMYT1 has an important role in the timing and fidelity of chromosome segregation
5 June 2026
Institute Authors (6)
Asma Belbelazi, Charlie Greenaway-Wells, Zoe Edwards, Wendy Trotter, Keren Dawson, Iain Hagan
Research Group
Cell Division
5 June 2026



